Mutations involving effectors of the mitogen-activated protein kinase (MAPK) pathway such as RET, BRAF, RAS, and NTRK1 occur in approximately 70% of patients with PTC and are associated with histopathological and biological tumor behavior [23]. Here, RET is linked to neoplasm.